Reports From the Field
Study shows reduction in recurrent stroke risk
More than 500,000 TIA (mini-strokes) could be prevented annually by using a combination of perindorpril, a high blood pressure medication, and indapamine (a diuretic), a new study has shown.
The study, sponsored by the National Stroke Association, was a 6,000-patient randomized trial conducted in 10 countries over the past five years.
The use of ACEON (also known as perindorpril) has was found to reduce the risk of secondary strokes by 50%. ACEON also reduces stroke-related dementia and serious cognitive impairments that stroke victims suffer by 50%.
"These results are the biggest single advance in secondary stroke prevention," investigators reported. ACEON lowers blood pressure and reduces the risk of blood clots, which is the significant cause of strokes. Secondary strokes are fatal about 25% of the time and there is great likelihood that a stroke victim will experience another stroke within five years of their first.
ACEON is a one-dose-a-day medication that is effective for 24 hours eliminating the problem of patients forgetting to take their medication.
"For the thousands of stroke survivors facing yet another debilitating stroke, the results of this trial are encouraging and give us another viable weapon in the fight against stroke-related disabilities and deaths," says Thomas G. Brott, MD, vice chairman of the National Stroke Association and senior associate consultant, department of neurology, Mayo Clinic in Jacksonville, FL.
To learn more information on strokes, visit www.stroke.org.
Send us Resource Bank items
If you have a new resource, conference, or seminar that can help other case managers do their jobs better or more efficiently, Case Management Advisor wants to hear from you.
Send items for publication to Mary Booth Thomas, Editor, Case Management Advisor, PO Box 740056, Atlanta, GA 30374. Phone: (770) 934-1440. E-mail: email@example.com.
CMA must receive news about conferences and seminars at least 12 weeks prior to the event to meet our publication deadlines.